臨床検査67巻7号

2023年07月発行

今月の特集 造血器・リンパ系腫瘍のWHO分類　第5版

骨髄増殖性腫瘍

著者： 枝廣陽子¹

所属機関： ¹順天堂大学医学部内科学血液学講座

ページ範囲：P.693 - P.697

Point

●慢性骨髄性白血病（CML）については，チロシンキナーゼ阻害薬による予後の改善に加えて，高リスク因子が重視された結果，移行期（AP）の診断基準は除外され，慢性期（CP），急性転化期（BP）の2つの分類に変更された．

●慢性好酸球性白血病（CEL）の診断基準については，好酸球増加の期間が6カ月から4週間に短縮され，疾患の呼称から非特定型が削除された．

●若年性骨髄単球性白血病（JMML）については，WHO分類改訂第4版では骨髄異形成/骨髄増殖性腫瘍（MDS/MPN）に分類されていたが，第5版では骨髄増殖性腫瘍（MPN）に分類変更となった．

参考文献

1）Jaffe ES, Harris NL, Stein H, et al：WHO Classification of Tumours of Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001

2）Vardiman JW, Harris NL, Brunning RD：The World Health Organization (WHO) classification of the myeloid neoplasms. Blood　100：2292-2302，2002

3）Tefferi A, Thiele J, Orazi A, et al：Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood　110：1092-1097，2007

4）Swerdlow SH, Campo E, Harris NL, et al：WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008

5）Arber DA, Orazi A, Hasserjian R, et al：The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood　127：2391-2405，2016

6）Swerdlow SH, Campo E, Harris NL, et al：WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Revised ed, IARC Press, Lyon, 2017

7）Baxter EJ, Scott LM, Campbell PJ, et al：Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet　365：1054-1061，2005

8）James C, Ugo V, Le Couédic JP, et al：A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature　434：1144-1148，2005

9）Kralovics R, Passamonti F, Buser AS, et al：A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med　352：1779-1790，2005

10）Levine RL, Wadleigh M, Cools J, et al：Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell　7：387-397，2005

11）Pikman Y, Lee BH, Mercher T, et al：MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med　3：e270，2006

12）Klampfl T, Gisslinger H, Harutyunyan AS, et al：Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med　369：2379-2390，2013

13）Nangalia J, Massie CE, Baxter EJ, et al：Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med　369：2391-2405，2013

14）Alaggio R, Amador C, Anagnostopoulos I, et al：The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia　36：1720-1748，2022

15）Khoury JD, Solary E, Abla O, et al：The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia　36：1703-1719，2022

16）Druker BJ, Talpaz M, Resta DJ, et al：Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med　344：1031-1037，2001

17）Hochhaus A, Larson RA, Guilhot F, et al：Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med　376：917-927，2017

18）Wang W, Cortes JE, Tang G, et al：Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood　127：2742-2750，2016

19）Soverini S, Bavaro L, De Benedittis C, et al：Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood　135：534-541，2020

20）Guglielmelli P, Pacilli A, Rotunno G, et al：Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood　129：3227-3236，2017

21）Rumi E, Boveri E, Bellini M, et al：Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget　8：101735-101744，2017

22）Vannucchi AM, Lasho TL, Guglielmelli P, et al：Mutations and prognosis in primary myelofibrosis. Leukemia　27：1861-1869，2013

23）Pardanani A, Lasho TL, Laborde RR, et al：CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia　27：1870-1873，2013

24）Pardanani A, Lasho T, Wassie E, et al：Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia　30：1924-1926，2016

25）Fang H, Ketterling RP, Hanson CA, et al：A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. Am J Clin Pathol　150：421-431，2018

26）Niemeyer CM, Flotho C：Juvenile myelomonocytic leukemia: who's the driver at the wheel?. Blood　133：1060-1070，2019